BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37144579)

  • 1. Broadly neutralizing antibodies for HIV treatment and cure approaches.
    Frattari GS; Caskey M; Søgaard OS
    Curr Opin HIV AIDS; 2023 Jul; 18(4):157-163. PubMed ID: 37144579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly neutralizing antibodies for the treatment and prevention of HIV infection.
    Caskey M
    Curr Opin HIV AIDS; 2020 Jan; 15(1):49-55. PubMed ID: 31764199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
    Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
    Thavarajah JJ; Hønge BL; Wejse CM
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of screening assays for use of broadly neutralizing antibodies in people with HIV.
    Lynch RM; Bar KJ
    Curr Opin HIV AIDS; 2023 Jul; 18(4):171-177. PubMed ID: 37265260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
    Cohen YZ; Caskey M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
    Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
    J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
    Paneerselvam N; Khan A; Lawson BR
    Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
    Williams WB; Wiehe K; Saunders KO; Haynes BF
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.
    Shapiro RL; Ajibola G; Maswabi K; Hughes M; Nelson BS; Niesar A; Pretorius Holme M; Powis KM; Sakoi M; Batlang O; Moyo S; Mohammed T; Maphorisa C; Bennett K; Hu Z; Giguel F; Reeves JD; Reeves MA; Gao C; Yu X; Ackerman ME; McDermott A; Cooper M; Caskey M; Gama L; Jean-Philippe P; Yin DE; Capparelli EV; Lockman S; Makhema J; Kuritzkes DR; Lichterfeld M
    Sci Transl Med; 2023 Jul; 15(703):eadh0004. PubMed ID: 37406137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
    Awan SF; Happe M; Hofstetter AR; Gama L
    Curr Opin HIV AIDS; 2022 Jul; 17(4):247-257. PubMed ID: 35762380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage.
    Wagh K; Seaman MS
    Curr Opin HIV AIDS; 2023 Jul; 18(4):164-170. PubMed ID: 37249911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.
    Spencer DA; Shapiro MB; Haigwood NL; Hessell AJ
    Front Public Health; 2021; 9():690017. PubMed ID: 34123998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality.
    Waters L; de Miguel-Buckley R; Poulin S; Arribas JR
    Clin Infect Dis; 2023 Mar; 76(6):1136-1141. PubMed ID: 36303321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect.
    Tipoe T; Fidler S; Frater J
    Curr Opin HIV AIDS; 2022 May; 17(3):162-170. PubMed ID: 35439790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
    Lee MJ; Collins S; Babalis D; Johnson N; Falaschetti E; Prevost AT; Ashraf A; Jacob M; Cole T; Hurley L; Pace M; Ogbe A; Khan M; Zacharopoulou P; Brown H; Sutherland E; Box H; Fox J; Deeks S; Horowitz J; Nussenzweig MC; Caskey M; Frater J; Fidler S
    Trials; 2022 Apr; 23(1):263. PubMed ID: 35382844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.